A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (NCT06230224)
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, Versus Standard of Care Therapy in Participants With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug versus Standard of Care (SOC) * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * Comparing the impact from the study drug versus SOC on quality-of-life and ability to complete routine daily activities
Who can join: Review the eligibility criteria below.
Location: Hospital Aleman — Ciudad Autonoma de Buenos Aires, Buenos Aires
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (81 Sites)
Showing the first 25 of 81 sites.
- Hospital Aleman — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Hospital Britanico de Buenos Aires — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Instituto Alexander Fleming — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Fundaleu - Fundacion Para Combatir La Leucemia — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Hospital Italiano de Buenos Aires — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Hospital Italiano de La Plata — La Plata, Buenos Aires
- Hospital Alta Complejidad El Cruce — San Juan Bautista, Buenos Aires
- Sanatorio Allende — Córdoba,
- Hospital Privado Universitario de Cordoba — Córdoba,
- Princess Alexandra Hospital — Woolloongabba, Queensland
- Olivia Newton John Cancer Wellness & Research Centre — Heidelberg, Victoria
- Hospital Santa Izabel - Santa Casa de Misericordia da Bahia — Salvador, Estado de Bahia
- Hospital Sao Rafael — Salvador, Estado de Bahia
- Ensino e Terapia de Inovacao Clinica Amo (Etica) — Salvador, Estado de Bahia
- Hospital Sirio Libanes Brasilia — Brasília, Federal District
- Uopeccan Hospital do Cancer de Cascavel — Cascavel, Paraná
- Hospital Erasto Gaertner — Curitiba, Paraná
- Hospital de Clinicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
- Centro Gaucho Integrado — Porto Alegre, Rio Grande do Sul
- Amaral Carvalho Hospital — Jaú, São Paulo
- Instituto Nacional de Cancer Jose Alencar Gomes da Silva — Rio de Janeiro,
- Hospital Sirio Libanes — São Paulo,
- A Beneficencia Portuguesa de Sao Paulo, Oncology House — São Paulo,
- Instituto D'Or De Pesquisa e Ensino — São Paulo,
- Hospital das Clinicas, Faculty of Medicine, University of Sao Paulo — São Paulo,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B-Cell Non-Hodgkin Lymphoma (B-NHL)
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies — Chicago, Illinois
- Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies — Miami, Florida
- Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma — Chicago, Illinois
Explore by condition: All B-Cell Non-Hodgkin Lymphoma (B-NHL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.